CIBC World Market
MBRX icon

CIBC World Market’s Moleculin Biotech MBRX Stock Holding History

CIBC World Market’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-72
Closed -$170K – 1191
2018
Q4 		$170K Buy
72
+32
+80% +$91.9K ﹤0.01% 1020
2018
Q3 		$143K Sell
40
-2
-5% -$7.54K ﹤0.01% 1084
2018
Q2 		$170K Buy
42
+13
+45% +$53.2K ﹤0.01% 1090
2018
Q1 		$117K Buy
+29
New +$125K ﹤0.01% 1119

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CIBC World Market's MBRX Position: Q1 2019 in Review

CIBC World Market sold out of Moleculin Biotech (MBRX) in Q1 2019, closing a stake of 72 shares — an estimated $170K sold.

CIBC World Market first reported a position in MBRX in Q1 2018 and held it in 4 quarters. The position peaked at $170K in Q4 2018. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2019.

  • CIBC World Market reported no remaining Moleculin Biotech position as of Q1 2019 after selling out during the quarter.
  • CIBC World Market sold 72 Moleculin Biotech shares in Q1 2019, an estimated $170K.
  • CIBC World Market first reported a position in Moleculin Biotech in Q1 2018 and held it in 4 quarters.
  • CIBC World Market's Moleculin Biotech position peaked at $170K in Q4 2018.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2019.

Based on CIBC World Market's 13F filing for Q1 2019, filed 9 May 2019.